

nnex Laboratories Limited

"AKASH GANGA" 3rd Floor, Plot No.144, Srinagar Colony, Hyderabad - 500073. Telangana, INDIA Tel: +91-40-67334400 (30Lines), 23746451, Fax: +91-40-67334433 Email: info@gennexlab.com | www.gennexlab.com CIN: L24230TG1990PLCO11168

Ref: GLL/Board/2018-19/0012

Date: 30/05/2018.

To Dy. General Manager, Bombay Stock Exchange Ltd., Phiroje Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. To The Secretary The Calcutta Stock Exchange Association Ltd., 7, Lyons Range, Calcutta - 700 001.

Dear Sir/Madam,

: Outcome of Board Meeting held today & Submission of Audited Financial Result Subject

for the 4th Quarter and Year Ended 31st March, 2018.

: Security ID : GENNEX & Script Code - 531739 Reference

Further to our letter dated.21.05.2018, in compliance with Regulation 30 and Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015, please find enclosed herewith the Audited Financial Results (Standalone and Consolidated) for the 4th Quarter and year ended 31st March, 2018 along with Auditors' Report and Form B (for Audit Report on modified opinion), as approved by the Board of Directors at their meeting held on today i.e, 30th May, 2018 from 11.30 A.M. to 1.00 P.M. and the extended session of the Meeting from 5.30 to $\frac{9.20}{}$ P.M.

Kindly bring this to the notice of the members of the Exchange.

porato

Thanking You,

Yours faithfully,

For Gennex Laboratories Ltd.,

T.M. Gopalakrishnan Whole Time Director

DIN: 03137458

Encl: as above

GENNEX LABORATORIES LIMITED

Registered Office: Sy.No.133, Bollaram, Jinnaram Mandal,

Dist : Sangareddy, Telangana - 502 325. INDIA CIN : L24230TG1990PLC011168

CN	DADTICH ADC							(Rs. In Lacs)
S No.	PARTICULARS		Quarter ended			e - Year Ended	Consolidated	
		31.03.2018		31.03.2017	31.03.2018	31.03.2017	31.03.2018	31.03.2017
1	In a company	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Income Revenue from Operations	1247.27	4400.64	1107.00				
	Other Income	1347.27	1188.61	1107.89	4377.88	4190.72	4377.88	4190.72
	Total Income	72.71	12.82	0.40	90.36	11.89	90.36	11.89
2	Expenses	1419.98	1201.43	1108.29	4468.24	4202.61	4468.24	4202.61
(a)	Cost of material consumed	774.41	710.56	CC1 7F	2567.72	2256.00	2567.72	
	Purchase of stock-in-trade	16.50	719.56 13.51	661.75	2567.72	2356.98	2567.72	2356.98
(c)	Changes in stock-in-trade and Work in Progress and stock in	131.65	-3.50	0.00 -45.60	30.01	0.00	30.01	0.00
(0)	trade	131.03	-3.30	-43.00	75.42	35.71	75.42	35.71
(d)	Employees Cost	184.11	122.92	157.24	554.57	405.00	55457	405.00
(e)	Depreciation	18.82	28.10	22.76	92.18	495.88 83.94	554.57	495.88
(f)	Other Expenses	275.29	270.38	298.23	1004.00	920.03	92.18	83.94
		270.23	270.50	250.25	1004.00	920.03	1004.00	920.03
	Total Other Expenses	275.29	270.38	298.23	1004.00	920.03	1004.00	920.03
	Total Expenses	1400.78	1150.97	1094.38	4323.90	3892.53	4323.90	3892.53
3	Total Profit before exceptional Items & Tax.	19.20	50.46	13.91	144.33	310.08	144.33	310.08
	Exceptional items	0.00	0.00	0.00	1.00	0.00		
	Total profit before tax	19.20	50.46	13.91	145.33	310.08	1.00	310.08
6	Tax expense for earlier years	-40.72	/ -19.60	36.58	-61.13	-3.07	-61.13	-3.07
7	Curent tax	-35.00	0.00	0.00	-35.00	-40.00	-35.00	-40.00
-	Deferred Tax	34.37	0.00	0.00	34.37		34.37	
	Total Tax Expenses	-41.36	-19.60	36.58		3.42		3.42
-	Net Movement in regulatory deferral account balances	0.00			-61.76	-39.65	-61.76	-39.65
10	related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00	0.00
11	Net profit Loss for the period from continuing operations	-22.15	30.86	-22.67	83.58	270.43	83.58	270.43
12	Profit (loss) from discontinued operations before tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
14	Net profit (loss) from discontinued operation after tax		No. 2 and the let			0.00	0.00	0.00
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00	(0.95)	(0.44
16	Total Profit (losss) for period	-22.15	30.86	-22.67	83.58	270.43	82.63	269.99
17	Other comprehensive income net of taxes	0.00	0.00	0.00	0.00	0.00	0.00	0.00
18	Total Comprehensive income for the period						0.00	0.00
	Total profit or loss, attributable to	-22.15	30.86	-22.67	83.58	270.43	82.63	269.99
-	Profit or loss, attributable to owners of parent				05.50		02.03	203.33
	Total Comprehensive income for theperido attributable to							
	Comprehensive income for the period attributable to owners of parent							
	Total comprehensive income for the period attrributable to owners of parent non controlling interests							
20	Details of equity share capital							
	Paid up equity share capital	1265.03	1265.03	1265.03	1265.03	1265.03	1265.03	1265.03
_	Face value of equity share capital	0.00001	0.00001	0.00001	0.00001	0.00001	0.00001	0.00001
21	Details of debt securities							
	Paid up debt capital							
_	Face value of debt securities							
_	Reserves excluding revaluation reserve							
	Debenture redemption reserve							
	Earnings per share	-0.018	0.024	-0.018	0.066	0.214	0.065	0.212
_	Earnings per share Earnings per equity share for continuing operations	-0.018	0.024	-0.018	0.066	0.214	0.065	0.213
	Basic Earnings (Loss) per share from continuing operations	-0.018	0.024	-0.018	0.066	0.214	0.065	0.213
-	Diluted earnings (loss) per share from continuing operations	-0.018	0.024	-0.018	0.066	0.214	0.065	0.213
				0	0	0	0	(
	Farnings per equity share for discontinued operations	0	Ol	111				
ii	Earnings per equity share for discontinued operations Basic Earnings (Loss) per share from discontinued operations	0	0	0	0	0	* 0	
ii								0

Hyderatad 5

Bas	sic earnings (loss) per share from discontinued operations	0	0	0	0	0	0	0
	uted earnings (loss) per share from continuing and continued operations	-0.018	0.024	-0.018	0.066	0.214	0.065	0.213
Deb	bt Equity Ratio				20.32	31.59	20.32	31.59
Deb	bt Service Coverage Ratio				0.29	0.71	0.29	0.71
Inte	erest service coverage Ratio				6.81	8.83	6.81	8.83

NOTES to the results:

- 1) The above audited financial results have been reviewed by the Audit Committee of the Board of Directors and taken on record at the meeting of Board of Directors held on May 30, 2018 and the Audited Report of the same has been carried out by the Auditors.
- 2) The statement has been prepared in accoedance with Companies (Indian Accounting Standard) Rules, 2015 (IndAS) prescribed under section 133 of Companies Act, 2013 and other prescribed accounting practices and policies to the extent possible.
- 3) The results pertaining to the relevant period of the previous year and year ended March,31,2017 stated in Ind AS format have not been subjeted to limited review or audit. However,the management has exercised necessary due diligence to ensure the financial results provided a true and fair view of its affairs.
- 4) The Reconciliation of the Net (Loss) / Profit reported in accordance with Indian GAAP to Total Comprehensive Income in accordance with the Ind AS is given below:

(Rs				
	Standalone - Year Ended	Consolidated- Year Ended		
Particulars	31.03.2017	31.03.2017		
	(audited)	(audited)		
Net (Loss) as per Previous IGAAP (Indian GAAP)	270.43			
Adjustment for Ind AS:				
- Net impact on investment - Fair Value Option through P&L				
- Deferred revenue on government grant				
- Depreciation on government grant				
- Actuarial Gain on Defined Benefit Plans considered under Other Comprehensive Income				
- Others				
- Deferred tax impact in respect of Ind AS adjustments				
Net (Loss) as per Ind AS	270.43			
Other Compreheasive Income:				
- Gain on Fair valuation of Investments				
- Actuarial (Gain) on Defined Benefit Plans (Net of tax)				
Total Comprehensive Income for the period as per Ind AS				

- 5) The management has assessed the Identification of reportable segements in accordance with the requirement of the Ind AS 108 Operating Segment and believes that the Company has only one reporable segment namely "Bulk Drugs, Biotech Products and Intermediates".
- 6) The figures for the quarter ended 31, March 2018 are the balancing figures between audites figures in respect of the year ended 31 march 2018 and the published year to date figures upto the 3rd quarter 31, December 2017 of the current financial year. Also the last figures upto the end of 3rd quarter were only review and not subject to audit.

aboratories

For Gennex Laboratories Limited

Whole Time Director

Place: Hyderabad Date: 30.05.2018



GENNEX LABORATORIES LIMITED
Registered Office: Sy.No.133, Bollaram, Jinnaram Mandal,
Dist: Sangareddy, Telangana - 502 325. INDIA
CIN: L24230TG1990PLC011168
Statement of Assets and Liabilities as at March, 2018

		Stand	dalone	Consolidated		
		As at	As at	As at	As at	
	Particulars	March 31, 2018	March 31, 2017	March 31, 2018		
		Audited	Audited		March 31, 2017	
Sl.no	Assets	in Lakhs	in Lakhs	Audited in Lakhs	Audited	
1	Non-Current Assets	III Editiis	III Lakiis	III Lakiis	in Lakhs	
	Property, Plant and Equipment	1,558.13	4.550.04			
	Capital work-in-progress	1,556.13	1,550.91	1,558.13	1,550.9	
	Investment property		23.20	•	23.2	
	Goodwill					
		•	•			
	Financial Assets					
	Investements in Associate	700.00	700.00	699.05	699.	
	Other Investments	1.00	1.00	1.00	1.0	
	Loans, non-current					
	Other non-current financial assets					
	Deferred Tax Assets (Net)					
	Other Non-current Assets	22.21	22.14	22.21	00	
	Total non-current assets	2,281.34	2,297.26		22.	
00		2,201.04	2,237.20	2,280.39	2,296.8	
2	CURRENT ASSETS					
	Inventories	222.00	000.04			
	Financial Assets	233.86	289.04	233.86	289.0	
	Trade receivables, current	1,045.91	* 1,029.56	1,045.91	1,029.5	
	Cash and Cash Equivalents	5.66	62.95	5.66	62.9	
	Bank balance other than cash and cash equivalents	96.17		96.17		
	Other current financial assets	1,381.94	1,242.02	1,381.94	1,242.0	
	Total Current financial assets	2,529.68	2,334.53	2,529.68	2,334.5	
	Current tax assets (net)			2,020.00	2,004.0	
	Other Current Assets	3.50	1.08	2.50		
	Total Current Assets	2,767.04		3.50	1.0	
		2,767.04	2,624.65	2,767.04	2,624.6	
-	Total Assets	5,048.38	4,921.92	5,047.43	4,921.4	
	EQUITY AND LIABILITIES					
	EQUITY					
E	Equity attributable to owners of parent					
	Equity Share capital	1,265.03	1,265.03	1,265.03	1,265.0	
	Other Equity	1,912.67	1,829.09	1,911.72	1,828.6	
	Total Equity	3,177.70	3,094.12	3,176.75	3,093.6	
200	IABILITIES			0,170.70	3,033.0	
1	Non-current Liabilities					
	Financial Liabilities:					
	Borrowings	34.86	8.55	34.86	8.5	
_	Other financial liabilities	-				
100	otal non current financial liabilities	34.86	8.55	34.86	8.5	
10	Other Non current Liabilities:					
	Deffered tax liabilities (Net)	60.51	94.89	60.51	94.89	
-	Deferred Government Grants, Non-current	8.27	10.01	8.27	10.0	
	otal Non-Current liabilities	103.64	113.45	103.64	113.4	
C	urrent Liabilities					
	Financial liabilities					
	Borrowings	212.16	375.16	212.16	375.16	
	Trade payables	1,235.88	945.73	1,235.88	945.73	
-	Other financial liabilities	270.97	337.44	270.97	337.4	
	otal Current financial liabilities	1,719.01	1,658.33	1,719.01	1,658.3	
10	ther current liabilities					
	Provisions, current	46.29	50.06	46.29	50.06	
	Current Tax Liabilities (Net)					
-	Deferred Government Grants, Current	1.74	5.96	1.74	5.96	
	otal current liabilities	48.03	56.02	48.03	56.02	
To	otal Liabilities	1,870.68	1,827.80	1,870.68	1,827.79	
1-	otal Equity and liabilities	5,048.38	4,921.92	5,047.43		
110						
	isclosure of notes on assets and liabilities	3,010.00	white the same of	1, 1	4,921.47	

For PPKG & CO

Chartered Accountants

Firm Registration No: 009655S

Partner

M.No. 205140 Place : Hyderabad

Date: 30th May, 2018

Laxmipat Baid Chief Financial Officer

felling

T.M.Gopalakrishnan

Whole Time Director

Chartered Accountants PPKG & Co

5-8-352, 701, 7th Floor, Raghav Ratna Towers, Chirag Ali Lane, Abids, Hyderabad - 500 001. Ph: +91-40-23205049, 66132176, 48517622 email: giri@ppkg.com • www.batgach.com

INDEPENDENT AUDITOR'S REPORT TO THE BOARD OF DIRECTORS OF GENNEX LABORATORIES LIMITED

- 1. We have audited the accompanying statement of standalone financial results of **Gennex Laboratories Limited (** ("the company") for the quarter and the year ended March 31, 2018 (the "Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('Listing Regulations')as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, which has been initiated by us for the purpose of identification.
- 2. This Statement, which is responsibility of the Company's Managementand have been reviewed by the Audit Committeeand approved by the Board of Directors, has been compiled from the related standalone financial Statements which has been prepared in accordance with the Accounting Standards prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the statement based on our audit of such standalone financial statements.
- 3. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the statement. The procedures selected depend on the auditors' judgement, including the assessment of the risks of material misstatement of the statement, whether due to fraud or error. In making those risk assessments, the auditors consider internal financial control relevant to the entity's preparation and fair presentation of the statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal financial control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

4. BASIS FOR QUALIFIED OPINION



Associate Office at:

• AHMEDABAD • ASSAM • BANGALORE • CHENNAI • DELHI

• GUWAHATI • JAIPUR • KOLKATA • MUMBAI • TRIVANDRUM

4. BASIS FOR QUALIFIED OPINION

The Balances of Current Assets, Other Non-Current Assets, Non Current Liabilities, Other Non-Current Liabilities, Current Liabilities & other Current Liabilities are subject to confirmations/reconciliations. The Impact of the same is unascertained.

5. QUALIFIED OPINION

In our opinion and to best of our information and according to the explanations given to us, except for the possible effects of the matters described in the Basis for Qualified Opinion paragraph;

- the Statement, together with the notes thereon are presented in the format prescribed under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 and SEBI Circular dated 5 July 2016; and
- the statement, gives true and fair view in conformity with Ind AS and other Accounting Principles generally accepted in India of the loss for the quarter and the profit for the year, the total Comprehensive Income and other financial information of the Company for the Quarter and year ended 31st March, 2018.

6. EMPHASIS OF MATTER

The Financial Statement which describes pending registration formalities for land acquired. Our opinion is not qualified in respect of this matter.

7. The Statement includes the results for the Quarter ended 31st March, 2018 being the balancing figure between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by erstwhile Auditors.

Other Matters

8. The Comparative figures of the Quarter and year ended March 31, 2017 prepared in accordance with applicable Indian Accounting Standards (Ind AS) were audited by the erstwhile auditors who had expressed modified opinion on these financial results/financial statements vide their reports dated 30.05.2017

For PPKG & Co., contered Accountants FRN 00965IS

> ari Lal Toshniwal Partner

> > M.No. 205140

Place: Hyderabad Date: 30.05.2018

PPKG & Co

5-8-352, 701, 7th Floor, Raghav Ratna Towers, Chirag Ali Lane, Abids, Hyderabad - 500 001. Ph: +91-40-23205049, 66132176, 48517622 email: giri@ppkg.com • www.batgach.com

INDEPENDENT AUDITOR'S REPORT TO THE BOARD OF DIRECTORS OF GENNEX LABORATORIES LIMITED

- 1. We have audited the accompanying statement of Consolidated financial results of Gennex Laboratories Limited ("the company") for the year ended March 31, 2018 and its Associate (together referred as "the Group") for the year ended March 31, 2018 ("the Statement"), attached hereto being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('Listing Regulations') as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, which has been initiated by us for the purpose of identification.
- 2. The Statement and the Consolidated Annual Financial Statements which form the basis for this Statement are the responsibility of the Company's Management and have been reviewed by the Audit Committee and approved by its Board of Directors, and have been prepared in accordance with the Accounting Standard prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules there under, as applicable, and other accounting Principles generally accepted in India. Our responsibility is to express an opinion on the Consolidated Financial Statements, based on our audit thereof.
- 3. We conducted our Audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the statement. The procedures selected depend on the auditors' judgement, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditors consider internal financial control relevant to the entity's preparation and fair presentation of the statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal financial control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



• AHMEDABAD • ASSAM • BANGALORE • CHENNAI • DELHI

• GUWAHATI • JAIPUR • KOLKATA • MUMBAI • TRIVANDRUM

Associate Office at

4. BASIS FOR QUALIFIED OPINION

The Balances of Current Assets, Other Non-Current Assets, Non Current Liabilities, Other Non-Current Liabilities, Current Liabilities & other Current Liabilities are subject to confirmations/reconciliations. The Impact of the same is unascertained.

5. QUALIFIED OPINION

In our opinion and to best of our information and according to the explanations given to us, except for the possible effects of the matters described in the Basis for Qualified Opinion paragraph;

- the Statement, together with the notes thereon are presented in the format prescribed under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 and SEBI Circular dated 5 July 2016; and
- ii. the statement, gives true and fair view in conformity with Ind AS and other Accounting Principles generally accepted in India of the loss for the quarter and profit for the year, the total Comprehensive Income and other financial information of the Company for the Quarter and year ended 31st March, 2018.

6. EMPHASIS OF MATTER

The Financial Statement which describes pending registration formalities for land acquired. Our opinion is not qualified in respect of this matter.

- 7. We did not audit the financial statements of Associate Company included in the Consolidated Financial Results, These financial statements have been audited by other auditors whose report have been furnished to us by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of this Associate is based solely on the reports of the other auditors.
- 8. The Statement includes the results for the Quarter ended 31st March, 2018 being the balancing figure between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by erstwhile Auditors.

Other Matters

9. The Comparative figures of the Quarter and year ended March 31, 2017 prepared in accordance with applicable Indian Accounting Standards (Ind AS) were audited by the erstwhile auditors who had expressed modified opinion on these financial results/financial statements vide their reports dated 30.05.2017

For PPKG & Co.,

daccountants

shniwal Partner

M.No. 205140

Place: Hyderabad Date: 30.05.2018



Gennex Laboratories Limited

"AKASH GANGA" 3rd Floor, Plot No.144, Srinagar Colony, Hyderabad - 500073. Telangana, INDIA Tel: +91-40-67334400 (30Lines), 23746451, Fax: +91-40-67334433 Email: info@gennexlab.com | www.gennexlab.com CIN: L24230TG1990PLCO11168

Ref: GLL/Board/2018-19/0013

Date: 30/05/2018.

To

Dy. General Manager,

Bombay Stock Exchange Ltd.,

Phiroje Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. To The Secretary

The Calcutta Stock Exchange Association Ltd.,

7, Lyons Range, Calcutta – 700 001.

Dear Sir/Madam,

Subject

: "Form B" for the Year Ended 31st March, 2018.

Reference : Security ID : GENNEX & Script Code 4 531739

Please find attached "Form B" (for Audit Report on modified opinion), as approved by the Board of Directors at its meeting held today in terms of Regulation 33(3)(d) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations..

Kindly bring this to the notice of the Members of the Exchange.

Thanking You,

Yours faithfully,

For Gennex Laboratories Ltd.,

Authorised Signatory

Encl: as above

"FORM B"

[Pursuant to Regulation 33(3)(d) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations

1.	Name of the Company	Gennex Laboratories Limited
2.	Annual financial statement for the year ended	31st March 2018
3	Type of Audit qualification	Ovalified
		Qualified
4.	Frequency of qualification	The below mentioned qualification that appears in the Balance Sheet is repetitive
5.	Draw attantion to relevant notes in the annual financial statements and management response to the qualification in the directors report.	Observation The Balances of Current Assets, other Non-Current Assets, Non-Current Liabilities, Other Non-Current Liabilities, Current Liabilities& other Current Liabilities are subject to confirmations/reconciliations. The Impact of the same is unascertained. Management Response As pointed out by the Statutory Auditors, the company has not obtained confirmation of balances of Advances, Deposits, Unsecured Loans, other liabilities, Trdae Receivables, Trade Payables and advance aganist Suppliers. The Company has made best of its efforts to obtain the same before signing the accounts for current financial year as well as for last financial year. Further, the management of the company confirms that balances shown in the books are true and correct as per their knowledge
6.	Additional comments for the board/audit committee chair	The Audit Committee took note of same and Formulated appropriate policies to aviod the same in future.
7.	To be signed by-	
	For Gennex Laboratories Limtied	For Gennex Laboratories Limtied
	T M Gopala Krishnan Executive Director DIN: 03137458	Laxmipat Baid Chief Finance Officer
	Y.Ravinder Reddy Chairman, Audit Committee DIN: 00011040	Auditor of the Company For PPKG & Co. (Firm No. 009655 S) (Giridhari Lal Toshniwal Partner M.No. 205140